華潤雙鶴(600062.SH)一字漲停 與真實生物戰略合作 簽署阿茲夫定片委託加工生產框架協議
格隆匯5月9日丨華潤雙鶴(600062.SH)競價一字漲停,封單超110萬手,報30.16元,總市值314.6億元,公司與真實生物簽署《戰略合作協議》及《阿茲夫定片委託加工生產框架協議》。由於雙方合作的傳聞發酵已久,近一個多月來華潤雙鶴備受資金追捧。公司股價自3月16日最低點震盪上行,近33個交易日累計漲超135%。據悉,目前在國產新冠特效藥研製方面,進度最快的有三家,分別是真實生物的阿茲夫定、君實生物的vv116和開拓藥業的普克魯胺。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.